BioRelix, a New Haven, Conn., developer of new antibiotics, raised $25.75 million in a first funding round, VentureWire reports (subscription required). The round included New Leaf Venture Partners, Aisling Capital, CHL Medical Partners, Novartis Venture Fund, Elm Street Ventures and Alexandria Real Estate Equities.

BioRelix is developing antibiotics that target what the company says are common stretches of bacterial RNA that control many functions essential for bacterial survival. The funding should allow the company to push a drug candidate into human tests by late 2009 or early 2010, its interim CEO told VentureWire.